News

Today the JTO, the official journal of the IASLC, published “PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the “Blueprint PD-L1 IHC Assay Comparison Project”. The IASLC has taken a leadership role in this important industrial-academic partnership to provide information on the analytical and clinical comparability of four PD-L1 IHC assays

DENVER – The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.

Los Angeles, CA (NOV 15, 2016) – More people die from lung cancer every year than any other cancers, and researchers are hard-pressed to find funding for studies that could improve treatments. As November is Lung Cancer Awareness Month, there is hopeful news.

November 2016 Newsletter

With the recent presentation of the data from Keynote-024, and the recent approval of pembrolizumab for high PD-L1 expressing tumors, the landscape of lung cancer oncology will change dramatically and for the better.

DENVER – Under the leadership of the International Association for the Study of Lung Cancer (IASLC), a consortium of lung cancer patient advocacy organizations and individuals have come together to develop a harmonized public awareness campaign for November’s annual Lung Cancer Awareness Month (LCAM).

DENVER – Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection.

Pages